HeartFlow, Inc. is recommended as a buy due to its AI-enabled platform that enhances coronary artery disease diagnosis through tools like FFRCT and Plaque Analysis, the latter of which is validated and soon to have its own billing code. With only about 2% market penetration and 41% year-over-year revenue growth, HeartFlow shows significant long-term growth potential, and its current valuation of roughly 8.4 times forward revenue is considered justified by the company's expanding product suite and clinical integration.